Analysts say the departure of the CBER head may alleviate overhang in the cell and gene therapy space. Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and ...

Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion ...

Aurobindo Pharma to acquire US-based Lannett for $250M, gaining a strategic local manufacturing base to offset tariffs and ...

Vinay Prasad, a top FDA official, suddenly departed after a series of controversial decisions about a Duchenne gene therapy ...

Psyence Biomedical Ltd. (Nasdaq: PBM) ('Psyence BioMed” or the 'Company”) is pleased to announce that its strategic partner, PsyLabs - a leader in the production of purified psychedelic compounds - ...

FDA’s drug center director, Dr. George Tidmarsh, will take over Prasad’s job in an acting role, according to an agency email ...

Authorities are investigating why two women fell ill at the Revolution Against Aging and Death Festival in Las Vegas.

Orr Inbar, CEO and co-founder of QuantHealth, unpacks the growing frustration over drug prices and the misperceptions fueling distrust in the pharmaceutical industry. With clinical trials now more ...

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for ...

The grant is subject to payment of fees and completion of final amendments and formalities. When issued, the patent claims ...

New narcolepsy treatments are being tested in the clinic, and recently, some of them have made promising strides. How far ...

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 ...